dactinomycin and calcipotriene

dactinomycin has been researched along with calcipotriene in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Alvarez, S; Binderup, L; López-Boado, YS; López-Otín, C; Puente, XS; Tolivia, J	1

Other Studies

2 other study(ies) available for dactinomycin and calcipotriene

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Growth inhibition of human breast cancer cells by 1,25-dihydroxyvitamin D3 is accompanied by induction of apolipoprotein D expression. Cancer research, 1997, Sep-15, Volume: 57, Issue:18 Topics: Antineoplastic Agents; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Calcitriol; Carcinoma; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Protein Synthesis Inhibitors; RNA, Messenger; RNA, Neoplasm; Time Factors; Tumor Cells, Cultured	1997

Article

Year

Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.

Current drug discovery technologies, 2004, Volume: 1, Issue:4

Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004

Growth inhibition of human breast cancer cells by 1,25-dihydroxyvitamin D3 is accompanied by induction of apolipoprotein D expression.

Cancer research, 1997, Sep-15, Volume: 57, Issue:18

Topics: Antineoplastic Agents; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Calcitriol; Carcinoma; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Protein Synthesis Inhibitors; RNA, Messenger; RNA, Neoplasm; Time Factors; Tumor Cells, Cultured

1997